Vazyme(SH:688105) Ge Long Hui A P P·2025-08-28 08:59Core Viewpoint - The company, 诺唯赞 (688105.SH), has signed a cooperation development agreement with 北京艺妙神州生物医药股份有限公司 to collaborate on cell therapy projects targeting Alzheimer's Disease, aiming to enhance early diagnosis and treatment options through technological innovation [1] Group 1: Partnership Details - The agreement involves establishing a joint venture company, tentatively named 北京唯妙生物科技有限公司, with both companies holding a 50% stake [1] - The registered capital of the joint venture is set at RMB 40 million, with the company contributing RMB 20 million [1] Group 2: Project Objectives - The collaboration aims to leverage both parties' strengths in Alzheimer's screening and cell therapy to develop comprehensive prevention and treatment solutions [1] - The focus is on technological breakthroughs in early diagnosis and upgrading intervention plans to enhance the health and memory of the elderly population [1]